In conclusion,GLP-1RAs may improve cognitive outcomes and brain function, particularly in the early stages of neurodegeneration and among high-risk T2DM populations. Further well-designed clinical trials are needed to evaluate the impacts ofGLP-1RAs on both the clinical progression and underlying pathology of dementia.
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretinanaloguesthat promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.GLP-1receptor ago...
Key TakeawaysGLP-1RAs are being explored for neurological conditions, including Alzheimer's, Parkinson's, and sleep disorders, with mixed but promising results. Semaglutide and otherGLP-1RAs show potential in reducing stroke risk and improving cardiovascular health, with significant trial data supporting these effects.
Disease-modifying treatments for major neurocognitive disorders, including Alzheimer's disease, Parkinson's disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...
Glucagon-like peptide1receptor agonists (GLP1-RAs) are treatments for diabetes and obesity that may also influence psychiatric outcomes. ObjectiveTo conduct a meta-analysis of randomized placebo-controlled trials to evaluate psychiatric, cognitive, and QOL outcomes withGLP1-RA treatment.
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders Article Open access 13 February 2025
The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity.
